GRM5 and Parkinson disease: The use of mavoglurant and diplaglurant (NCT01336088), named as negative allosteric antagonists of mGluR5, and foliglurax (NCT03162874), named as a positive allosteric agonist of mGlu4, have been tested in PD [30,31].